Go Pro
NASDAQ:ALGS

Aligos Therapeutics Q1 2026 Earnings Report

Aligos Therapeutics logo
$5.54 +0.04 (+0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$5.70 +0.16 (+2.85%)
As of 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aligos Therapeutics EPS Results

Actual EPS
-$2.21
Consensus EPS
-$2.29
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Aligos Therapeutics Revenue Results

Actual Revenue
$2.83 million
Expected Revenue
$0.25 million
Beat/Miss
Beat by +$2.58 million
YoY Revenue Growth
N/A

Aligos Therapeutics Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 7, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Aligos Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aligos Therapeutics Earnings Headlines

Aligos Therapeutics (NASDAQ:ALGS) Upgraded at Jefferies Financial Group
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases, viral infections and related conditions. The company uses its research platforms to discover and advance small-molecule therapies designed to address significant unmet medical needs.

Its development programs have included treatments for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH) and viral respiratory diseases. The company’s hepatitis B pipeline has included capsid assembly modulators, while its MASH efforts have included therapies intended to improve liver health and reduce disease progression. Aligos has also pursued antiviral programs targeting coronaviruses and other infectious diseases.

Founded in 2018, Aligos Therapeutics is headquartered in South San Francisco, California. Its programs are developed through clinical research and collaborations intended to support potential commercialization in international markets. The company is led by President and Chief Executive Officer Lawrence M. Blatt.

View Aligos Therapeutics Profile